ストックスクリーナーアプリを入手
15.07
7.26%
1.02
前日終値:
$14.05
開ける：
$13.32
24時間の取引高:
521.03K
Relative Volume:
1.93
時価総額：
$8.87M
収益：
-
当期純損益:
$-8.28M
株価収益率:
-2.7104
EPS:
-5.56
ネットキャッシュフロー:
$-7.99M
1週間 パフォーマンス:
+84.00%
1か月 パフォーマンス:
+92.71%
6か月 パフォーマンス:
+156.73%
1年 パフォーマンス:
-14.57%
1日の値動き範囲:
$13.32
$18.99
1週間の範囲:
$7.8501
$41.80
52週間の値動き範囲:
$5.01
$54.95
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Company Profile
名前
Quoin Pharmaceuticals Ltd Adr
セクター
電話
97299741444
住所
23 HATA'AS STREET, KFAR SABA
QNRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
QNRX
Quoin Pharmaceuticals Ltd Adr
|
15.08 | 8.26M | 0 | -8.28M | -7.99M | -5.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
411.46 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
476.50 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.80 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
814.64 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.94 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Quoin Pharmaceuticals Ltd Adr (QNRX) 最新ニュース
Quoin Pharmaceuticals (NASDAQ:QNRX) Receives Sell (E) Rating from Weiss Ratings - Defense World
Pre Market Movers: NBTX, IMTX, QNRX See Big Swings - RTTNews
Why NioCorp Developments Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Quoin Pharmaceuticals (QNRX) Stock Is Skyrocketing Friday: What's Going On? - Benzinga
Quoin Pharmaceuticals stock soars after securing premium-priced funding - Investing.com
Quoin Pharmaceuticals secures up to $104.5 million in private placement - Investing.com
Quoin Pharmaceuticals finalizes separation agreement with former CFO - Investing.com
Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Up 2.8% – Still a Buy? - Defense World
Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Quoin Pharmaceuticals (QNRX) and RegenXBio (RGNX) - The Globe and Mail
Quoin (QNRX) Q2 Loss Beats Estimates - The Motley Fool
Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - The Globe and Mail
Quoin Pharmaceuticals stock rises after positive clinical updates - Investing.com India
Quoin Pharmaceuticals advances rare disease pipeline with two active trials - Investing.com India
Quoin Pharmaceuticals advances rare disease pipeline with two active trials By Investing.com - Investing.com Nigeria
Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Price Down 2.9% – Here’s Why - Defense World
MINISO Group Holding Limited Unsponsored ADR (NYSE:MNSO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Quoin Pharmaceuticals CFO Gordon Dunn to depart following mutual agreement - Investing.com India
Quoin Pharmaceuticals (NASDAQ:QNRX) Trading Down 1.2% – Should You Sell? - Defense World
Quoin Pharmaceuticals receives FDA rare pediatric disease designation for QRX003 - Investing.com
FDA grants rare pediatric disease designation for Netherton syndrome drug - Investing.com
Quoin announces FDA clearance to initiate second whole body QRX003 NS study - TipRanks
FDA clears Quoin’s new Netherton syndrome study By Investing.com - Investing.com South Africa
FDA clears Quoin’s new Netherton syndrome study - Investing.com
Quoin Pharmaceuticals announces EMA grants ODD for QRX003 - TipRanks
Retail Buzz Intensifies Around Quoin Pharma Stock After Positive Pediatric Skin Study Data By Stocktwits - Investing.com India
Why Quoin Pharmaceuticals (QNRX) Stock Is Exploding Higher Wednesday - Benzinga
Quoin Pharmaceuticals announces initial positive clinical data for QRX003 - TipRanks
Quoin reports progress in pediatric skin disorder study By Investing.com - Investing.com India
Quoin Pharmaceuticals reports Q1 EPS ($6.50) vs ($38.73) last year - TipRanks
Quoin Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com India
Quoin Pharmaceuticals regains Nasdaq compliance - Investing.com
Quoin Pharmaceuticals regains compliance with Nasdaq minimum bid price rule - TipRanks
Quoin Pharmaceuticals regains Nasdaq compliance with bid price - Investing.com
Quoin Pharmaceuticals releases second episode of ‘Living with Netherton’ series - TipRanks
Upcoming Stock Splits This Week (April 7 to April 11) – Stay Invested - The Globe and Mail
Quoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirements - Investing.com India
Quoin Pharmaceuticals reports positive clinical data for rare disease treatment - Investing.com
QNRX Stock Plummets to 52-Week Low at $0.26 Amid Market Struggles - Investing.com
Quoin seeks patent for skin disease treatment QRX003 - Investing.com
Quoin Pharmaceuticals reports promising Netherton Syndrome treatment - Investing.com
Quoin Pharmaceuticals launches Netherton awareness campaign - Investing.com
Quoin reports positive results in Netherton Syndrome study - Investing.com
Quoin Pharmaceuticals CEO Michael Myers acquires $250,000 in shares - Investing.com
Quoin Pharmaceuticals granted extension to meet Nasdaq listing - Investing.com
Quoin Pharmaceuticals COO acquires $28,737 in company shares - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Quoin Pharmaceuticals sets terms for $6.5 million offering - Investing.com
Trading Halts Explained - MarketBeat
Major Indexes Muted Following Strong Jobs Report - Schaeffer's Investment Research
Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada - Yahoo Finance
Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis - MarketBeat
Quoin Pharmaceuticals Ltd Adr (QNRX) 財務データ
収益
当期純利益
現金流量
EPS
Quoin Pharmaceuticals Ltd Adr (QNRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Myers Michael | Chief Executive Officer |
Dec 23 '24 |
Buy |
0.45 |
555,556 |
250,000 |
602,808 |
| Dunn Gordon | Chief Financial Officer |
Dec 23 '24 |
Buy |
0.45 |
122,221 |
54,999 |
151,077 |
| Culverwell Anthony James | Director |
Dec 23 '24 |
Buy |
0.45 |
100,000 |
45,000 |
100,317 |
5.20%
1.12%
大文字化:
|
ボリューム (24 時間):